Keyword: Precision BioSciences
Precision Bio files $100 million IPO for its off-the-shelf CAR-Ts after raising $110 million in a series B and signing a hep B alliance with Gilead.
Gilead is pursuing a gene therapy for hepatitis B, aiming to eliminate viral infections in vivo by using Precision BioSciences’ editing platform.
The series B round sets the genome editing specialist up to take its lead, off-the-shelf CAR-T therapy into clinical trials.
The financing gives Laura Deming, who started work on the fund before turning 18, $22 million to invest in companies working on age-related diseases.